Clinical Trial: FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06865664) titled 'FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma' on March 07.

Brief Summary: Background:

Rhabdomyosarcoma (RMS) is a cancer of soft tissues. It often appears in children. RMS cancer cells produce a protein called FGFR4. Researchers want to try a new kind of treatment for RMS: They will collect a person s own T cells, a type of immune cell; then they will change the T cells so they are better able to target and attack RMS tumor cells. The modified T cells are chimeric antigen receptor (CAR) T cells. The treatment in this study is called FGFR4-CAR T cells.

Obj...